CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Income Statement [Abstract]
Revenues		$ 12,131	$ 12,680	$ 35,961	$ 39,062
Costs and expenses:
Cost of sales	[1]	2,529	2,602	7,188	7,611
Selling, informational and administrative expenses	[1]	3,016	3,260	8,919	10,110
Research and development expenses	[1]	2,360	2,283	6,216	5,827
Amortization of intangible assets		898	1,212	2,688	3,578
Restructuring charges and certain acquisition-related costs		4	365	435	295
(Gain) on completion of Consumer Healthcare JV transaction		0	(8,087)	(6)	(8,087)
Other (income)/deductions––net		1,148	319	507	537
Income from continuing operations before provision/(benefit) for taxes on income	[2]	2,176	10,727	10,014	19,190
Provision/(benefit) for taxes on income		(26)	3,047	968	2,566
Income from continuing operations		2,202	7,680	9,046	16,625
Discontinued operations––net of tax		0	4	0	4
Net income before allocation to noncontrolling interests		2,202	7,684	9,046	16,628
Less: Net income attributable to noncontrolling interests		8	4	25	19
Net income attributable to Pfizer Inc.		$ 2,194	$ 7,680	$ 9,022	$ 16,609
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.39	$ 1.38	$ 1.62	$ 2.98
Discontinued operations––net of tax (in dollars per share)		0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		0.39	1.38	1.62	2.98
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		0.39	1.36	1.60	2.92
Discontinued operations––net of tax (in dollars per share)		0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.39	$ 1.36	$ 1.60	$ 2.92
Weighted-average shares––basic		5,557	5,545	5,552	5,581
Weighted-average shares––diluted		5,633	5,649	5,622	5,690

[1] Excludes amortization of intangible assets, except as disclosed in Note 9A and Notes to Consolidated Financial Statements––Note 1L. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets in our 2019 Financial Report.

[2] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income of $44 million in the third quarter of 2020 and $43 million in the third quarter of 2019, and $196 million in the first nine months of 2020 and $184 million in the first nine months of 2019 from our investment in ViiV. See Note 4.